Our findings also indicate that the function of DR4 and DR5 is regulated separately intracellularly and the Egr-1 status of a tumour may indicate the sensitivity of the tumour towards death receptor agonist therapeutics. This evidence concerns the gene TNFRSF10A and neoplasm.